



## NEWS RELEASE

### **Biosensors Granted U.S. Patent Covering Drug Technology**

*Provides Rights to Biolimus A9 for Use With Drug-Eluting Stents and Variety of other Medical Applications*

Singapore, 23, May 2007 – Biosensors International Group, Ltd. (Bloomberg: BIG SP), today announced the granting of a patent from the United States Patent and Trademark Office for its Biolimus A9™ drug. This U.S. patent (patent number 7220755) covers the Biolimus A9 composition of matter and its further use in a number of medical treatments through varied formulations, including the use on polymer-coated stents, polymer free stents, ointments, microbeads, tablets and others for the treatment of restenosis, wounds, vascular injury and inflammation, and organ transplant rejection.

The grant of this patent further strengthens Biosensors' intellectual property portfolio especially related to its drug-eluting stent technology. Two years ago, Biosensors was also granted a U.S. patent that covers the use of antirestenosis, immunosuppressive drugs used in combination with a biodegradable drug-release polymer coating on a stent.

Yoh-Chie Lu, Chairman and CEO of Biosensors said, "We are delighted to have this patent granted to us. We now have confirmation of our proprietary rights to manufacture, license and use Biolimus A9 in drug-eluting stents and other medical applications. While we remain focused on commercializing our BioMatrix drug-eluting stent that incorporates Biolimus A9 as the unique anti-restenosis drug, we are also excited by the potential alternative uses of Biolimus A9."

"Expanding intellectual property is particularly important in a segment such as the highly competitive multi-billion dollar drug-eluting stent market. We will continue to secure, leverage and when necessary, vigorously defend our intellectual property", Mr. Lu further commented.

#### **About Biosensors International Group, Ltd**

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a biodegradable polymer and a proprietary anti-restenosis drug. It is pursuing three separate drug-eluting stent programs, BioMatrix®, Axxion™, and BioMatrix® Freedom™, a polymer-free drug-eluting stent, and has licensed aspects of its drug-eluting stent technology to four companies.

#### **Forward Looking Statements**

*Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "project" or "continue" or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.*

#### **Media & Investor Relations**

##### **Singapore**

Mr. Loh Chee Mun  
Senior Vice President  
Tel: (65) 621-35708  
Email: [cm.loh@biosensors.com](mailto:cm.loh@biosensors.com)

##### **United States**

Allen & Caron Inc.  
Mr. Matt Clawson  
Executive Vice President, Investor Relations  
Tel: (1) 949-4744300  
Email: [matt@allencaron.com](mailto:matt@allencaron.com)